NCT01160172View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 19, 2010

Primary Completion Date

August 23, 2012

Study Completion Date

August 23, 2012

Conditions
Infections, Staphylococcal
Interventions
BIOLOGICAL

Staphylococcal investigational vaccine GSK2392103A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392105A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392106A

intramuscular vaccination according to protocol schedule

BIOLOGICAL

Staphylococcal investigational vaccine GSK2392019A

intramuscular vaccination according to protocol schedule

DRUG

Saline placebo

intramuscular vaccination according to protocol schedule

Trial Locations (1)

7100

GSK Investigational Site, La Louvière

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01160172 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter